Trial intelligence / Profile preview

Skeletal muscle-derived cell implantation for fecal incontinence

2021-001376-42Phase 3Active

Sponsor
Innovacell
Start
Jul 2021
Modality
Stem Cell Therapies → Cell Therapies
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of autologous skeletal muscle-derived cells in fecal incontinence (FI) (2 arms), sponsored by Innovacell. Started Jul 2021; status: active.

02

Drugs

autologous skeletal muscle-derived cells
03

Conditions

fecal incontinence (FI)

Beyond the preview

Go deeper on 2021-001376-42.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2021-001376-42.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call